BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2026 9:17:10 AM | Browse: 5 | Download: 38
 |
Received |
|
2025-11-11 12:50 |
|
Peer-Review Started |
|
2025-11-11 12:50 |
|
First Decision by Editorial Office Director |
|
2025-12-17 08:03 |
|
Return for Revision |
|
2025-12-17 08:03 |
|
Revised |
|
2025-12-22 14:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-09 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-09 09:45 |
|
Articles in Press |
|
2026-01-09 09:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-27 07:31 |
|
Publish the Manuscript Online |
|
2026-05-14 09:17 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Integrating immune-related metrics with personalize first-line immunochemotherapy in human epidermal growth factor receptor 2-negative advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Han Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yu-Han Yang, Assistant Professor, West China School of Medicine, Sichuan University, No. 17 People’s South Road, Chengdu 6100041, Sichuan Province, China. yyh_1023@163.com |
| Key Words |
Gastric cancer; Programmed death ligand 1 inhibitor; Predictive model; Neutrophil-to-lymphocyte ratio; C-reactive protein-albumin-lymphocyte index; Efficacy |
| Core Tip |
This study developed and validated a novel survival prediction model for advanced human epidermal growth factor receptor 2 negative gastric cancer patients receiving immunotherapy combined with chemotherapy. A retrospective analysis of 200 patients identified programmed death ligand 1 expression, microsatellite instability, tumor-node-metastasis stage, tumor differentiation, neutrophil-to-lymphocyte ratio, and C-reactive protein-albumin-lymphocyte index as independent prognostic factors. Based on these factors, nomogram models for progression-free survival and overall survival were constructed and validated using the concordance index and area under the curve. The results showed good discrimination ability in both the training and validation sets, indicating that the model effectively predicts patient survival outcomes and provides strong support for personalized treatment decisions. |
| Publish Date |
2026-05-14 09:17 |
| Citation |
Yang YH. Letter to the Editor: Integrating immune-related metrics with personalize first-line immunochemotherapy in human epidermal growth factor receptor 2-negative advanced gastric cancer. World J Gastrointest Oncol 2026; 18(5): 116411 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i5/116411.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i5.116411 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
